Sanofi (SNY) Shareholder Renaissance Group Has Upped Its Holding by $1.70 Million as Stock Price Rose; As Carolina Finl New (CARO) Share Value Declined, Jacobs Asset Management Upped Stake by $591,024

Sanofi (NYSE:SNY) Logo

Jacobs Asset Management Llc increased its stake in Carolina Finl Corp New (CARO) by 7.89% based on its latest 2018Q2 regulatory filing with the SEC. Jacobs Asset Management Llc bought 14,072 shares as the company’s stock declined 3.63% while stock markets rallied. The institutional investor held 192,500 shares of the major banks company at the end of 2018Q2, valued at $8.26 million, up from 178,428 at the end of the previous reported quarter. Jacobs Asset Management Llc who had been investing in Carolina Finl Corp New for a number of months, seems to be bullish on the $741.49 million market cap company. The stock decreased 0.45% or $0.15 during the last trading session, reaching $33.05. About 84,762 shares traded or 23.40% up from the average. Carolina Financial Corporation (NASDAQ:CARO) has risen 18.67% since December 8, 2017 and is uptrending. It has outperformed by 3.05% the S&P500.

Renaissance Group Llc increased its stake in Sanofi (SNY) by 11.9% based on its latest 2018Q2 regulatory filing with the SEC. Renaissance Group Llc bought 42,422 shares as the company’s stock rose 12.28% with the market. The institutional investor held 398,906 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $15.96M, up from 356,484 at the end of the previous reported quarter. Renaissance Group Llc who had been investing in Sanofi for a number of months, seems to be bullish on the $107.10B market cap company. The stock decreased 0.53% or $0.23 during the last trading session, reaching $43.48. About 826,951 shares traded. Sanofi (NYSE:SNY) has declined 11.24% since December 8, 2017 and is downtrending. It has underperformed by 26.86% the S&P500. Some Historical SNY News: 17/04/2018 – Sanofi: Advent Would Acquire Zentiva for EUR1.9B; 13/04/2018 – Advent International closes in on deal for Sanofi’s generics unit; 29/05/2018 – Adaptive Biotechnologies Announces a Collaboration with Sanofi to Use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual; 11/03/2018 – Umer Raffat set up a call with $MDCO execs tomorrow. Focus is on $ESPR, $MDCO and $AMGN reactions after $REGN and $SNY scored on high-risk PCSK9 study – DON’T MISS:; 27/03/2018 – FDA: New Drug Application (NDA): 206538 Company: SANOFI US SERVICES; 16/05/2018 – Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis; 01/05/2018 – REGENERON & SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB); 01/05/2018 – Sanofi/Regeneron’s one-two punch on PCSK9 price and health data wins a key convert as Express Scripts creates exclusive formulary deal $REGN $SNY $AMGN $ESRX; 30/05/2018 – JPMorgan International Equity Adds Glaxo, Cuts Sanofi; 03/04/2018 – STAT Plus: Sanofi and Regeneron encounter more payer resistance over new eczema drug – this time, in the U.K

Renaissance Group Llc, which manages about $2.82B US Long portfolio, decreased its stake in Aetna Inc (NYSE:AET) by 26,664 shares to 183,771 shares, valued at $33.72M in 2018Q2, according to the filing. It also reduced its holding in Home Depot Inc (NYSE:HD) by 33,101 shares in the quarter, leaving it with 155,657 shares, and cut its stake in Alphabet Inc Class A.

More notable recent Sanofi (NYSE:SNY) news were published by: Bizjournals.com which released: “Health Care Digest: Chelsea Clinton’s shout out, Verily shelves ‘smart lens’ for diabetes, an East Bay biotech’s hunt for employees and more – San Francisco Business Times” on November 19, 2018, also Bizjournals.com with their article: “Takeda, Shire shareholders approve $62B tie-up – Boston Business Journal” published on December 05, 2018, Seekingalpha.com published: “It May Be Better To Avoid Sanofi – Seeking Alpha” on September 05, 2018. More interesting news about Sanofi (NYSE:SNY) were released by: Fool.com and their article: “Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals – The Motley Fool” published on December 01, 2018 as well as Seekingalpha.com‘s news article titled: “Sanofi: Can Dividend Growth Be Reignited? – Seeking Alpha” with publication date: May 29, 2018.

Among 13 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 9 Hold. Therefore 23% are positive. Sanofi-aventis Sa had 30 analyst reports since October 15, 2015 according to SRatingsIntel. The stock of Sanofi (NYSE:SNY) has “Underweight” rating given on Friday, December 1 by Morgan Stanley. The company was downgraded on Tuesday, January 23 by Barclays Capital. The stock of Sanofi (NYSE:SNY) has “Buy” rating given on Thursday, September 8 by Berenberg. The rating was upgraded by Barclays Capital to “Equal-Weight” on Wednesday, November 15. The stock has “Underperform” rating by BNP Paribas on Thursday, December 10. The stock has “Buy” rating by Citigroup on Friday, August 10. The firm has “Hold” rating by HSBC given on Wednesday, August 30. Cowen & Co maintained the shares of SNY in report on Tuesday, September 5 with “Hold” rating. The company was upgraded on Thursday, October 15 by Morgan Stanley. The stock of Sanofi (NYSE:SNY) earned “Neutral” rating by Goldman Sachs on Monday, November 7.

More notable recent Carolina Financial Corporation (NASDAQ:CARO) news were published by: Foxbusiness.com which released: “Dow clears 25K as the Nasdaq sits at a record high – Fox Business” on July 13, 2018, also Nasdaq.com with their article: “F.N.B. Ratings Reiterated by Moody’s, Outlook Downgraded – Nasdaq” published on April 03, 2018, Nasdaq.com published: “Hancock Whitney (HWC) Q3 Earnings In Line, Revenues Increase – Nasdaq” on October 17, 2018. More interesting news about Carolina Financial Corporation (NASDAQ:CARO) were released by: Nasdaq.com and their article: “New Strong Sell Stocks for August 28th – Nasdaq” published on August 28, 2018 as well as Seekingalpha.com‘s news article titled: “Stocks To Watch: Calling Up Animal Spirits – Seeking Alpha” with publication date: September 22, 2018.

Jacobs Asset Management Llc, which manages about $1.11B and $556.56M US Long portfolio, decreased its stake in First Bancorp P R (NYSE:FBP) by 150,000 shares to 800,000 shares, valued at $6.12 million in 2018Q2, according to the filing. It also reduced its holding in Citizens Finl Group Inc (NYSE:CFG) by 62,500 shares in the quarter, leaving it with 462,500 shares, and cut its stake in Newmark Group Inc.

Sanofi (NYSE:SNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.